How many institutions held VOR - Vor Biopharma Inc. - Common Stock, $0.0001 par value per share in Q4 2025?

53 institutional investors reported VOR - Vor Biopharma Inc. - Common Stock, $0.0001 par value per share for Q4 2025. Use the holders table for investor-level position and value details.

Vor Biopharma Inc. - Common Stock, $0.0001 par value per share (VOR)

Q: What does CUSIP 929033207 represent in this 13F holders report?

CUSIP 929033207 is the security identifier for VOR - Vor Biopharma Inc. - Common Stock, $0.0001 par value per share used to aggregate holder disclosures.

CUSIP: 929033207

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / Common Stock, $0.0001 par value per share
Shares outstanding: 43,408,727
Total 13F shares: 25,530,116
Share change: +20,825,485
Total reported value: $331,798,548
Put/Call ratio: 35%
Price per share: $13.08
Number of holders: 53
Value change: +$261,399,708
Number of buys: 45
Number of sells: 12

Quarterly Holders Quick Answers

What is CUSIP 929033207?
CUSIP 929033207 identifies VOR - Vor Biopharma Inc. - Common Stock, $0.0001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Related Filing Research

Latest 13F filings for newly reported positions.
Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
Latest 10-Q/10-K reports for financial context tied to this issuer.
Recent insider transactions for executive and insider activity.
SEC investors directory and top value investors for manager drilldown.
Back to full security ownership history.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026
Previous quarter: Q3 2025

Recent filing periods for CUSIP 929033207:

Q1 2026 Q4 2025 Q3 2025

Top shareholders of VOR - Vor Biopharma Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
RA CAPITAL MANAGEMENT, L.P.	13F 13D/G	Company	14% from 13D/G	1,982,301	$96,577,705	—	30 Sep 2025	13F 13D/G
ForGrowth III PA B.V.	13D/G	—	10%	10,237,714	$81,492,203	+$25,772,203	18 Dec 2025	13D/G
Verve Capital Ltd	13D/G	Verve Capital Limited	9.9%	4,297,464	$58,273,612	+$47,958,533	31 Dec 2025	13D/G
Reprogrammed Interchange LLC	13D/G 3/4/5	10%+ Owner	18%	1,204,442	$48,045,191	$0	15 Oct 2025	13D/G 3/4/5
FMR LLC	13D/G 13F	Company	6.5%	2,526,170	$37,185,222	+$25,579,283	31 Dec 2025	13D/G 13F
Venrock Healthcare Capital Partners III, L.P.	13D/G	—	9.9%	2,216,075	$30,049,977	+$19,734,899	31 Dec 2025	13D/G
VR Adviser, LLC	13F	Company	1.2%	499,966	$24,358,344	—	30 Sep 2025	13F
Paradigm Biocapital Advisors LP	13D/G	—	4.5%	1,750,000	$23,730,000	$0	31 Dec 2025	13D/G
GREAT POINT PARTNERS LLC	13D/G	—	3.3%	1,370,107	$18,578,651	+$1,839,021	31 Dec 2025	13D/G
FCPM III SERVICES B.V.	13F	Company	0.87%	379,640	$18,496,061	—	30 Sep 2025	13F
Frazier Life Sciences Public Fund, L.P.	13D/G	—	5.8%	2,258,001	$17,973,688	$0	18 Dec 2025	13D/G
Qiming Venture Partners VIII-HC, L.P.	13D/G	—	2.8%	1,089,767	$14,777,241	+$8,047,792	31 Dec 2025	13D/G
Ariose Capital Management Ltd	13F	Company	0.25%	110,173	$5,367,629	—	30 Sep 2025	13F
VANGUARD GROUP INC	13F	Company	0.24%	105,190	$5,124,857	—	30 Sep 2025	13F
5AM Ventures VI, L.P.	13D/G 3/4/5	Andrew J. Schwab · 10%+ Owner	3.5%	4,422,863	$4,422,863	$0	08 Jul 2025	13D/G 3/4/5
UBS Group AG	13F	Company	0.17%	75,909	$3,698,287	—	30 Sep 2025	13F
JOHNSON & JOHNSON	13F	Company	0.09%	53,732	$2,617,823	—	30 Sep 2025	13F
TANG CAPITAL MANAGEMENT LLC	13F	Company	0.12%	50,000	$2,436,000	—	30 Sep 2025	13F
BlackRock, Inc.	13F	Company	0.08%	34,530	$1,682,294	—	30 Sep 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.06%	27,392	$1,334,785	—	30 Sep 2025	13F
Woodline Partners LP	13F	Company	0.06%	27,363	$1,333,125	—	30 Sep 2025	13F
Sarissa Capital Management LP	13F	Company	0.06%	25,399	$1,237,439	—	30 Sep 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.06%	24,764	$1,206,502	—	30 Sep 2025	13F
Polymer Capital Management (HK) LTD	13F	Company	0.05%	21,248	$1,035,203	—	30 Sep 2025	13F
Qing Che Zuraw	3/4/5	Chief Development Officer	— mixed-class rows	1,155,732 mixed-class rows	$993,304	—	05 Dec 2025	3/4/5
JANE STREET GROUP, LLC	13F	Company	0.04%	16,753	$816,206	—	30 Sep 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.04%	15,786	$769,094	—	30 Sep 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.03%	14,600	$711,312	—	30 Sep 2025	13F
Robert Ang	3/4/5	PRESIDENT AND CEO, Director	— mixed-class rows	1,736,318 mixed-class rows	$510,338	—	06 May 2025	3/4/5
STATE STREET CORP	13F	Company	0.02%	9,054	$441,111	—	30 Sep 2025	13F
Virtu Financial LLC	13F	Company	0.02%	8,104	$395,000	—	30 Sep 2025	13F
Nathan D. Jorgensen	3/4/5	CHIEF FINANCIAL OFFICER	— mixed-class rows	289,403 mixed-class rows	$331,455	—	06 May 2024	3/4/5
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.01%	6,250	$304,500	—	30 Sep 2025	13F
Scientech Research LLC	13F	Company	0.01%	6,097	$297,046	—	30 Sep 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.01%	6,075	$295,974	—	30 Sep 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.01%	5,686	$277,022	—	30 Sep 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.01%	4,754	$231,615	—	30 Sep 2025	13F
Squarepoint Ops LLC	13F	Company	0.01%	4,729	$230,397	—	30 Sep 2025	13F
Trustees of Columbia University in the City of New York	13F	Company	0.01%	4,595	$223,868	—	30 Sep 2025	13F
MORGAN STANLEY	13F	Company	0.01%	4,456	$217,096	—	30 Sep 2025	13F
Eyal C. Attar	3/4/5	CHIEF MEDICAL OFFICER	— mixed-class rows	441,625 mixed-class rows	$179,808	—	13 Feb 2025	3/4/5
Bollard Group LLC	13F	Company	0.01%	2,777	$135,000	—	30 Sep 2025	13F
Tirtha Chakraborty	3/4/5	Chief Sci Off & Head Tech Ops	— mixed-class rows	532,416 mixed-class rows	$121,752	—	06 May 2025	3/4/5
Amy Quinlan	3/4/5	Vice President of Finance	— class O/S missing	50,312	$43,268	—	06 Nov 2024	3/4/5
Han Wook Choi	3/4/5	Chief Financial Officer	— mixed-class rows	366,280 mixed-class rows	$33,844	—	01 May 2025	3/4/5
Caitong International Asset Management Co., Ltd	13F	Company	0%	110	$5,359	—	30 Sep 2025	13F
JPMORGAN CHASE & CO	13F	Company	0%	78	$3,800	—	30 Sep 2025	13F
MAI Capital Management	13F	Company	0%	40	$1,949	—	30 Sep 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	0%	4	$195	—	30 Sep 2025	13F
Allworth Financial LP	13F	Company	0%	3	$147	—	30 Sep 2025	13F

Institutional Holders of Vor Biopharma Inc. - Common Stock, $0.0001 par value per share (VOR) as of Q4 2025

As of 31 Dec 2025, Vor Biopharma Inc. - Common Stock, $0.0001 par value per share (VOR) was held by 53 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 25,530,116 shares. The largest 10 holders included RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., Frazier Life Sciences Management, L.P., FMR LLC, VR ADVISER, LLC, Paradigm Biocapital Advisors LP, GREAT POINT PARTNERS LLC, NEXTBio Capital Management LP, Caligan Partners LP, and VANGUARD GROUP INC. This page lists 53 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.